RA0279

antibody from Oursmab

Targeting: GREM1 CKTSF1B1, CRAC1, DAND2, DRM, gremlin, HMPS

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0279

Provider

Oursmab

Product name

Ginisortamab (Biosimilar Reference Antibody) (GREM1)

Antibody type

Monoclonal

Description

Ginisortamab is an investigational, fully human immunoglobulin G4 P (IgG4P) monoclonal antibody designed for the potential treatment of gastrointestinal (GI) tumors. It functions as a specific inhibitor of Gremlin-1 (GREM1), a secreted protein. By binding with high affinity to Gremlin-1, ginisortamab neutralizes its biological activity, preventing it from interacting with its target ligands. Gremlin-1 is a key antagonist of the bone morphogenetic protein (BMP) pathway, and its inhibition by ginisortamab aims to restore normal BMP signaling, which is crucial for cellular differentiation, tissue homeostasis, and suppressing epithelial-to-mesenchymal transition (EMT)¡ªprocesses often dysregulated in cancer progression and metastasis, particularly in GI tumors.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.